Jam

Endeavour Mining’s May 22, 2025 AGM saw strong shareholder engagement, with 72.79% of issued shares represented. All directors were re-elected with approval rates exceeding 94%, demonstrating investor trust. Key resolutions passed include the Directors’ Remuneration Policy (81.67%) and near-unanimous support for compensation reports (98.53%). Shareholders overwhelmingly authorized capital management actions, including share allotment and buybacks (99.98% approval), reflecting confidence in financial strategy. With 242.2 million shares issued and 103,147 in treasury, the company maintains disciplined capital flexibility. Analysts view the outcomes as reinforcing governance rigor amid gold market uncertainties, positioning Endeavour to advance strategic initiatives.

Guardian Pharmacy Services (NYSE: GRDN) priced its public offering of 7.5 million Class A shares at $21.00 each, including 6.06 million shares from existing stockholders and 1.44 million new shares. Proceeds from new shares will repurchase 1.44 million converted Class B shares, preventing net dilution. Raymond James leads underwriting with a 30-day option for 1.13 million additional shares. The SEC-approved offering, effective May 22, supports Guardian’s strategy to balance capital allocation while serving long-term care facilities in 38 states.

IMPACT Silver (TSXV: IPT) raised C$3.93 million via a dual-tranche private placement, combining C$1.66 million from a LIFE offering (C$0.20/unit) and C$2.27 million from standard units (C$0.18/unit), with tiered warrants exercisable at C$0.24–0.26. Proceeds will accelerate exploration at Mexico’s Plomosas zinc-lead-silver project and revive the Zacualpan silver district, alongside operational upgrades. The financing introduces 15% dilution (20.9M shares), potentially reaching 31.7% if warrants fully convert. While immediate liquidity from LIFE shares benefits investors, challenges include declining Zacualpan silver grades and discontinuous mineralization at Plomosas requiring new discoveries to offset risks.

Journey Energy Inc. (JOY/JRNGF) strengthened its governance at its 2025 AGM, with shareholders approving all resolutions by wide margins. Key outcomes included maintaining a six-member board (85.67% support), director reappointments (79.42%-83.01% approval), KPMG’s auditor retention (97.37%), and adoption of governance modernization measures (82.10%). The re-elected board will prioritize operational continuity, balancing conventional energy production with emissions reduction initiatives. Analysts highlight high approval ratings as a competitive advantage, noting alignment with strategic goals like drilling efficiency and renewable partnerships outlined in the 2025 roadmap.

Silvercorp Metals reported robust fiscal 2025 results with annual revenue up 39% to $298.9 million and adjusted net income of $75.1 million. Q4 revenue surged 76% YoY to $75.1 million, though a $20.6 million derivative charge led to a $7.6 million net loss. The company achieved record-low cash costs ($2.49/oz silver net of byproducts) and doubled cash reserves to $369 million. Key developments include the $181 million Adventus Mining acquisition and $138.6 million operating cash flow funding growth projects. Despite base metals volatility, Silvercorp maintained its dividend streak and strengthened its position in precious/base metals markets.

Hims & Hers Health introduced a six-month Wegovy® subscription at $549/month, a 15% discount on average retail prices, to expand access to prescription weight-loss care. The limited-time offer via telehealth includes consultations, nutritional tools, and progress tracking, leveraging Novo Nordisk’s expanded production. CEO Andrew Dudum emphasized affordability in chronic care, while analysts note the model bridges payer-patient cost gaps. The initiative aligns with a 212% annual rise in metabolic health consultations, reflecting consumer demand for preventive solutions. Promotion runs through June 30, 2025, with eligibility criteria on the company’s platform. Hims & Hers continues offering compounded alternatives and behavioral programs in the $100 billion wellness sector.

Guess?, Inc., WHP Global, and Marcolin announced a four-year eyewear licensing deal for their jointly owned rag & bone label, targeting the $114B global market. Launching Q1 2026, the collection blends urban aesthetics with artisanal craftsmanship, reflecting rag & bone’s ethos of merging heritage tailoring with modern utility. Marcolin, leveraging 30+ years in luxury eyewear, will produce angular, versatile designs aligned with Gen Z’s “quiet luxury” trends. The partnership extends rag & bone’s lifestyle offerings post-2024 acquisition, while Marcolin strengthens its premium portfolio after €545.8M revenue in 2023. Distribution spans 48 boutiques, e-commerce, and select retailers, supported by Marcolin’s AI customization tech.

Solis Minerals (ASX: SLM) is advancing a major copper-gold exploration campaign in Peru’s coastal copper belt, launching three key projects: a 2,500m drilling program at Chancho al Palo (targeting porphyry/IOCG systems), permitted 5,000m drilling at Ilo Este by 2025, and an IP survey near Southern Copper’s Toquepala mine. Positioned in a region producing 19% of global copper, Solis benefits from full asset ownership and proximity to infrastructure. Risks include regulatory delays and copper price volatility ($4.50/lb). Peru aims to double copper output by 2030, driven by green tech demand. SLM shares rose 4.3% post-announcement, with A$12.6M working capital supporting operations.

PPG’s 2024 Sustainability Report highlights progress toward 2030 goals, with 41% of its portfolio now classified as sustainable. Key achievements include an 18% reduction in Scopes 1 & 2 emissions through renewable energy initiatives, a 6% drop in Scope 3 emissions, and 48% of manufacturing waste repurposed. The company’s Italy solar project cuts 390 metric tons of CO₂ annually, while flagship products like ENVIRO-PRIME® EPIC200X reduce client emissions by 3,500 tons yearly. PPG also invested $16.4 million in community revitalization since 2015. Analysts note its strategy aligns with a $12 trillion sustainability-driven market, blending compliance with clean-tech innovation. The report underscores PPG’s role in transforming regulatory challenges into growth opportunities.

Amphastar Pharmaceuticals (NASDAQ: AMPH) will participate in the 2025 Jefferies Global Healthcare Conference on June 5, featuring CFO Bill Peters and EVP Jacob Liawatidewi in a fireside chat. The company aims to highlight its growth strategy, including pipeline advancements in complex generics and proprietary drugs like BAQSIMI and Primatene MIST. With Q1 2025 R&D spending up 18%, analysts note its focus on innovative drug delivery systems, such as inhalation therapies, to disrupt traditional markets. The event, accessible via webcast, underscores Amphastar’s efforts to strengthen investor engagement and showcase manufacturing capabilities amid expanding portfolios in diabetes and emergency care.